NCT05623410Unknown3 期
A Randomized, Double-Blind, Active-Control, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of "ATGC-110" Compared to "Xeomin®" in Patients Who Need Moderate or Severe Glabellar Line Improvement
ATGC Co., Ltd.2 个研究点 分布在 2 个国家目标入组 300 人开始时间: 2022年10月11日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 300
- 试验地点
- 2
- 主要终点
- Improvement rate (%) of glabellar lines at maximum frown according to the investigator's on-site evaluation at week 4 compared to the baseline
研究概览
简要总结
Efficacy and safety of the investigational product, ATGC-110, was evaluated in comparison with Xeomin for a total of 16 weeks after the administration in treatment of glabellar frown lines.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 19 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male and female subjects aged between 19 to 65 years
- •Subjects assigned a glabellar line severity grade of 2 or greater (moderate) at maximum frown assessed by the Investigator
- •Subjects who provide written consent to voluntarily participate in the study after receiving and understanding a detailed explanation of the study
排除标准
- •Subjects with diseases that may affect neuromuscular function, such as Myasthenia gravis, Lambert-Eaton syndrome, Amyotrophic lateral sclerosis, or motor neuropathy etc.)
- •Subjects with the history of eyelid paralysis or ptosis
- •Subjects with significant facial asymmetry
- •Subjects whose glabellar lines cannot be satisfactorily improved with physical methods since lines are not flattened even using hands
- •Infection, dermatological condition or scar at the treatment injection sites
- •Subjects currently suffering acute diseases
- •Subjects with the history of excessive alcohol consumption or drug addiction
- •Condition including anxiety disorder, or any other significant psychiatric disorder (e.g. depression), in the investigator's opinion
- •Subjects with concomitant illnesses that make them unsuitable for participation in the study by the Investigator such as malignant tumors, immunodeficiency (immune deficiency), kidney disease, liver disease, or lung disease
- •Subjects with the history of treatment of the glabellar region (including the forehead) such as face lifting, permanent implants, or fillers
- •Subjects who have received other procedures that may affect the assessment of the glabellar or forehead lines during the following periods; Within 6 months of screening: main ingredient hyaluronic acid skin filler, dermal resurfacing, chemical/mechanical skin peeling, skin peeling, Dermal photorejuvenation; Within 12 months of screening: Dermal fillers other than the main ingredient hyaluronic acid, nonpermanent soft tissue fillers
- •Subjects who have received medication that inhibits neuromuscular function within the 4 weeks prior to screening such as muscle relaxants, anticholinergics, benzodiazepines and similar drugs, benzamides, tetracycline antibiotics, lincomycin antibiotics, and aminoglycoside antibiotics
- •Subjects who have taken retinoid drugs (Isotretinoin, Alitretinoin, etc.) during the following period; Oral and systemic use: within 6 months of screening Topical applied on the face: within 3 months of screening
- •Subjects who have received aspirin or NSAIDs within 7 days prior to administration of the IP (Use of low-dose aspirin (325 mg/day or less) to prevent blood clotting is allowed).
- •Subjects taking anticoagulants or antiplatelet agents (Use of low-dose aspirin (325 mg/day or less) to prevent blood clotting is allowed)
- •Subjects who are allergic or sensitive to the IP or its components
- •Subjects who have received botulinum toxin preparations within 6 months from the time of screening
- •Female subjects of childbearing age who do not agree to practice contraception using medically allowed contraceptive methods during the study period (hormonal contraception, IUD (intrauterine device) or IUS (intrauterine system), tubal ligation, dual protection (using a combination of male condom, female condom, cervical cap, contraceptive diaphragm, or contraceptive sponge)
- •Pregnant or lactating women
- •Subjects planning a facial cosmetic procedure (skin fillers, photorejuvenation, chemical/mechanical peeling, etc.) during the study period
- •Subjects who have participated in other clinical trials within 30 days prior to participating in this study and have received an IP or medical device during the previous clinical studies
- •Subjects directly related to the investigator (e.g. a dermatologist or plastic surgeon)
- •Individuals who are not eligible for this study for any reason as per the Investigator's discretion
结局指标
主要结局
Improvement rate (%) of glabellar lines at maximum frown according to the investigator's on-site evaluation at week 4 compared to the baseline
时间窗: 4 weeks after the administration
Investigators will assess subjects' glabellar lines with Facial Wrinkle Scale (FWS) at maximal frown; 0=none, 1=mild, 2=moderate or 3=severe. Only the subjects whose FWS score is 0- or 1-grade when it's assessed and ≥ 2-grade improvement from baseline will be defined as their glabellar lines are improved.
次要结局
- The percentage of subjects whose FWS score is 0- or 1-grade at maximal frown according to the investigator's on-site evaluation at week 4, 8, 12, and 16(4, 8, 12 and 16 weeks after the administration)
- Improvement rate (%) of glabellar lines at maximum frown according to the investigator's on-site evaluation at weeks 8, 12, and 16 compared to the baseline(8, 12 and 16 weeks after the administration)
- Improvement rate (%) of glabellar lines at rest according to the investigator's on-site evaluation at weeks 4, 8, 12, and 16 compared to the baseline(4, 8, 12 and 16 weeks after the administration)
- Evaluation of subjects' satisfaction at weeks 4, 8, 12, and 16(4, 8, 12 and 16 weeks after the administration)
- The percentage of subjects whose FWS score is 0- or 1-grade at rest according to the investigator's on-site evaluation at week 4, 8, 12, and 16(4, 8, 12 and 16 weeks after the administration)
- The percentage of subjects whose FWS score is 0- or 1-grade at rest evaluated through photographs by the independent evaluator at week 4, 8, 12, and 16(4, 8, 12 and 16 weeks after the administration)
- The percentage of subjects whose FWS score is improved ≥ 2 grade improvement according to the subject's evaluation at week 4, 8, 12, and 16(4, 8, 12 and 16 weeks after the administration)
- The percentage of subjects whose FWS score is imporved ≥ 2 grade improvement at maximal frown according to the investigator's on-site and subject's evaluation at weeks 4, 8, 12, and 16(4, 8, 12 and 16 weeks after the administration)
- Improvement rate (%) of glabellar lines at maximum frown evaluated through photographs by the independent evaluator at weeks 4, 8, 12, and 16 compared to the baseline(4, 8, 12 and 16 weeks after the administration)
- Improvement rate (%) of glabellar lines at rest evaluated through photographs by the independent evaluator at weeks 4, 8, 12, and 16 compared to the baseline(4, 8, 12 and 16 weeks after the administration)
- The percentage of subjects whose FWS score is 0- or 1-grade at maximal frown evaluated through photographs by the independent evaluator at week 4, 8, 12, and 16(4, 8, 12 and 16 weeks after the administration)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular InflammationInflammationPainCataractNCT02235272Xigen SA339
已完成
3 期
Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation and PainInflammationPainCataractNCT02508337Xigen SA309
已完成
3 期
Clinical Study to Test the Efficacy and Safety of ACYC to Treat Moderate to Severe AcneAcneNCT01701024Bausch Health Americas, Inc.498
已完成
3 期
A Comparative Study Between Two Formulations of the Ciprofloxacin Hydrochloride + Hydrocortisone Otic SuspensionOtitis ExternaNCT00980876Farmoquimica S.A.224
终止
2 期
Safety and Efficacy of ATG003 in Patients With Wet Age-Related Macular Degeneration (AMD)Macular DegenerationNCT00414206CoMentis343